Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EuroNet-PHL-C2: Treatment for Classical Hodgkin Lymphoma in Children and Adolescents
NCT02797717Phase 3Recruiting
- Start
- Nov 2015
- Primary completion
- Dec 2022
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands, Covalent Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dacarbazine, etoposide, doxorubicin, cyclophosphamide, prednisone and 1 more in classical Hodgkin lymphoma (cHL). Started Nov 2015; status: recruiting.
02
Drugs
dacarbazineetoposidedoxorubicincyclophosphamideprednisone
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT02797717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02797717.